iVeena develops ocular drug products that eliminate the need for eye drop application and painful injections.
iVeena has five products in the late pre-clinical and research phases. Targeted indications include post-surgery cataract inflammation, macular degeneration (Wet AMD), diabetic retinopathy, and glaucoma.iVeena Delivery Systems, Inc. was founded in 2006 by Bala Ambati and is based in Salt Lake City, Utah.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 10, 2017 | Grant | $224.99K | 1 | National Science Foundation | — | Detail |
Dec 18, 2015 | Seed | $600K | 2 | — | — | Detail |
Sep 25, 2015 | Seed | $1.30M | 1 | Park City Angels | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |
Park City Angels | — | Seed |
PC Squared, LLC | — | Seed |